Review



mouse anti human fgfr1 abs  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals mouse anti human fgfr1 abs
    Figure 1. <t>FGFR1</t> as an immune adjuvant to combine with ICI in HNSCC mouse models. (a) FGFR1 expression in mouse HNSCC cell lines (MOC1) was examined by Western blotting. (b) Experimental schema. C57BL/6 mice were intradermally injected with MOC1 (1x106). PD173074 (20 mg/kg) and anti-PD-1 Ab (200 μg/mice) was administered 3 times per week from day 18 (tumor size: 7–8 mm). (c) Tumor growth curves. Control (Red), anti-PD-1 Ab monotherapy (Blue), PD173074 monotherapy (Yellow), and combination therapy with PD173074 and anti-PD-1 Ab (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (*p < .05, **p < .01, ***<0.001, one-way ANOVA). (d) The mice were sacrificed on day 42, and the percentages of CD4+ T cells and CD8+ T cells in TILs were evaluated with flow cytometry. (e) A representative image of MHC-class I or MHC-class II expression in immunohistochemistry on tumor (Day 42). MHC-class I (central) and MHC-class II (right) was enhanced by PD173074. H&E staining was shown in the left. Scale bars represent 100 µm. (f, g) MHC-class I and MHC-class II expression on MOC1 incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. MOC1 was treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Red: isotype control, Green: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (f) Representative data of flow cytometry. (g) Averages values of mean fluorescence intensity (MFI) by FGFR-TKIs. (*p < .05, **p < .01, ***<0.001, Student’s t test).
    Mouse Anti Human Fgfr1 Abs, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+fgfr1+abs/Mouse+anti-Human+IgG1+Fc+Secondary+Antibody+(2C11)/10__1080_slash_2162402x__2021__2021619-48-5-10
    Average 93 stars, based on 7 article reviews
    mouse anti human fgfr1 abs - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma"

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma

    Journal: OncoImmunology

    doi: 10.1080/2162402x.2021.2021619

    Figure 1. FGFR1 as an immune adjuvant to combine with ICI in HNSCC mouse models. (a) FGFR1 expression in mouse HNSCC cell lines (MOC1) was examined by Western blotting. (b) Experimental schema. C57BL/6 mice were intradermally injected with MOC1 (1x106). PD173074 (20 mg/kg) and anti-PD-1 Ab (200 μg/mice) was administered 3 times per week from day 18 (tumor size: 7–8 mm). (c) Tumor growth curves. Control (Red), anti-PD-1 Ab monotherapy (Blue), PD173074 monotherapy (Yellow), and combination therapy with PD173074 and anti-PD-1 Ab (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (*p < .05, **p < .01, ***<0.001, one-way ANOVA). (d) The mice were sacrificed on day 42, and the percentages of CD4+ T cells and CD8+ T cells in TILs were evaluated with flow cytometry. (e) A representative image of MHC-class I or MHC-class II expression in immunohistochemistry on tumor (Day 42). MHC-class I (central) and MHC-class II (right) was enhanced by PD173074. H&E staining was shown in the left. Scale bars represent 100 µm. (f, g) MHC-class I and MHC-class II expression on MOC1 incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. MOC1 was treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Red: isotype control, Green: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (f) Representative data of flow cytometry. (g) Averages values of mean fluorescence intensity (MFI) by FGFR-TKIs. (*p < .05, **p < .01, ***<0.001, Student’s t test).
    Figure Legend Snippet: Figure 1. FGFR1 as an immune adjuvant to combine with ICI in HNSCC mouse models. (a) FGFR1 expression in mouse HNSCC cell lines (MOC1) was examined by Western blotting. (b) Experimental schema. C57BL/6 mice were intradermally injected with MOC1 (1x106). PD173074 (20 mg/kg) and anti-PD-1 Ab (200 μg/mice) was administered 3 times per week from day 18 (tumor size: 7–8 mm). (c) Tumor growth curves. Control (Red), anti-PD-1 Ab monotherapy (Blue), PD173074 monotherapy (Yellow), and combination therapy with PD173074 and anti-PD-1 Ab (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (*p < .05, **p < .01, ***<0.001, one-way ANOVA). (d) The mice were sacrificed on day 42, and the percentages of CD4+ T cells and CD8+ T cells in TILs were evaluated with flow cytometry. (e) A representative image of MHC-class I or MHC-class II expression in immunohistochemistry on tumor (Day 42). MHC-class I (central) and MHC-class II (right) was enhanced by PD173074. H&E staining was shown in the left. Scale bars represent 100 µm. (f, g) MHC-class I and MHC-class II expression on MOC1 incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. MOC1 was treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Red: isotype control, Green: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (f) Representative data of flow cytometry. (g) Averages values of mean fluorescence intensity (MFI) by FGFR-TKIs. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Techniques Used: Adjuvant, Expressing, Western Blot, Injection, Control, Flow Cytometry, Immunohistochemistry, Staining, Incubation, Fluorescence

    Figure 2. The changes of HLA and CIITA expression on HNSCC cell lines by FGFR1-TKIs. (a) FGFR1 expression in human HNSCC cell lines was examined by Western blotting. Jurkat (leukemia cells) was used as a negative control. (b, c) HLA-class I and HLA-DR and expression on HNSCC cell lines incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Green: isotype control, Red: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (b) Representative data of flow cytometry. (c) Averages values of mean fluorescence intensity (MFI). (d-g) FGFR-TKIs (3 μM) upregulated CIITA expression in HNSCC cell lines. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. (d) Representative data of Western blotting without IFN-γ. (e) Quantitative analysis of protein expression. (f) Representative data of Western blotting with IFN-γ. (g) Quantitative analysis of protein expression. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).
    Figure Legend Snippet: Figure 2. The changes of HLA and CIITA expression on HNSCC cell lines by FGFR1-TKIs. (a) FGFR1 expression in human HNSCC cell lines was examined by Western blotting. Jurkat (leukemia cells) was used as a negative control. (b, c) HLA-class I and HLA-DR and expression on HNSCC cell lines incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Green: isotype control, Red: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (b) Representative data of flow cytometry. (c) Averages values of mean fluorescence intensity (MFI). (d-g) FGFR-TKIs (3 μM) upregulated CIITA expression in HNSCC cell lines. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. (d) Representative data of Western blotting without IFN-γ. (e) Quantitative analysis of protein expression. (f) Representative data of Western blotting with IFN-γ. (g) Quantitative analysis of protein expression. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Techniques Used: Expressing, Western Blot, Negative Control, Incubation, Flow Cytometry, Control, Fluorescence

    Figure 5. Direct killing of FGFR1 expressing HNSCC cells by FGFR1305-319-reactiveCD4+ T cell lines. (a) FGFR1305-319-reactive CD4+ T cell lines were co-cultured with HLA-DR matched or unmatched HNSCC cell lines expressing FGFR1 for 48 hr. K1 and K3 were restricted to HLA-DR4, and K2 was restricted to HLA-DR53. The cell lines used were HSC2 (HLA-DR13), HSC3 (HLA-DR15), HSC4 (HLA-DR1,4, and 53), Sa-3 (HLA-DR9, 10, and 53), and HPC-92Y (HLA-DR4, 9, and 53). HNSCC cell lines were treated with 500 U/ml IFN-γ for 48 hr before the assay. IFN-γ production in the supernatants was evaluated by ELISA. (b) Granzyme-B production from FGFR1305-319-reactive CD4+ T cell line (K1: HLA-DR4 restricted) was assessed in supernatants co-cultured with HLA-DR matched or unmatched HNSCC cell lines. (c) Killing activity of FGFR1305-319-reactive CD4+ T cell line (K1) was evaluated by co-culturing with CSFE-labeled HNSCC cell lines for 6 hr with various E: T (Effector: Target cells) ratio, and measuring percentages of CFSE+ 7-AAD+ dead cells with flow cytometry. (d) Representative data of flow cytometry in the killing assay (Effector to target ratio was 20:1). Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).
    Figure Legend Snippet: Figure 5. Direct killing of FGFR1 expressing HNSCC cells by FGFR1305-319-reactiveCD4+ T cell lines. (a) FGFR1305-319-reactive CD4+ T cell lines were co-cultured with HLA-DR matched or unmatched HNSCC cell lines expressing FGFR1 for 48 hr. K1 and K3 were restricted to HLA-DR4, and K2 was restricted to HLA-DR53. The cell lines used were HSC2 (HLA-DR13), HSC3 (HLA-DR15), HSC4 (HLA-DR1,4, and 53), Sa-3 (HLA-DR9, 10, and 53), and HPC-92Y (HLA-DR4, 9, and 53). HNSCC cell lines were treated with 500 U/ml IFN-γ for 48 hr before the assay. IFN-γ production in the supernatants was evaluated by ELISA. (b) Granzyme-B production from FGFR1305-319-reactive CD4+ T cell line (K1: HLA-DR4 restricted) was assessed in supernatants co-cultured with HLA-DR matched or unmatched HNSCC cell lines. (c) Killing activity of FGFR1305-319-reactive CD4+ T cell line (K1) was evaluated by co-culturing with CSFE-labeled HNSCC cell lines for 6 hr with various E: T (Effector: Target cells) ratio, and measuring percentages of CFSE+ 7-AAD+ dead cells with flow cytometry. (d) Representative data of flow cytometry in the killing assay (Effector to target ratio was 20:1). Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Techniques Used: Expressing, Cell Culture, Enzyme-linked Immunosorbent Assay, Activity Assay, Labeling, Flow Cytometry

    Figure 6. The existence of FGFR1-reactive precursor T cells in HNSCC patients. (a) PBMCs from HNSCC patients were co-cultured with FGFR1305-319 peptides for 2 cycles every one week. T cell response to FGFR305-319 peptide was assessed by measuring IFN-γ production in the supernatants using ELISA. Anti-HLA-DR mAb was used to assess HLA restriction of the T cells. PADRE peptide was used as a positive control. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test). (b) The clinical characteristics and peptide-reactivity of the 6 HNSCC patients. <: less than the lower limit of detection.
    Figure Legend Snippet: Figure 6. The existence of FGFR1-reactive precursor T cells in HNSCC patients. (a) PBMCs from HNSCC patients were co-cultured with FGFR1305-319 peptides for 2 cycles every one week. T cell response to FGFR305-319 peptide was assessed by measuring IFN-γ production in the supernatants using ELISA. Anti-HLA-DR mAb was used to assess HLA restriction of the T cells. PADRE peptide was used as a positive control. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test). (b) The clinical characteristics and peptide-reactivity of the 6 HNSCC patients. <: less than the lower limit of detection.

    Techniques Used: Cell Culture, Enzyme-linked Immunosorbent Assay, Positive Control

    Related Articles

    Membrane:

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the Miute TM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human β-actin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the MiuteTM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Incubation:

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the Miute TM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human β-actin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the MiuteTM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Western Blot:

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the Miute TM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human β-actin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the MiuteTM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Imaging:

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the Miute TM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human β-actin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
    Article Snippet: The tumor cell line proteins extracted using the MiuteTM Total Protein Extraction Kit (Invent Biotechnologies, Inc.) were subjected to electrophoresis on NuPAGE Bis–Tris gels (Invitrogen, Thermo Fisher Scientific Inc.) and transferred to an Immobilon-P membrane (Merck Millipore). .. The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific). .. Class II transactivator (CIITA) expression was evaluated using mouse anti-CIITA Abs (sc-13556, 7–1 H, Santa Cruz Biotechnology, Santa Cruz, CA).



    Similar Products

    mouse anti human fgfr1 abs  (Novus Biologicals)
    93
    Novus Biologicals mouse anti human fgfr1 abs
    Figure 1. <t>FGFR1</t> as an immune adjuvant to combine with ICI in HNSCC mouse models. (a) FGFR1 expression in mouse HNSCC cell lines (MOC1) was examined by Western blotting. (b) Experimental schema. C57BL/6 mice were intradermally injected with MOC1 (1x106). PD173074 (20 mg/kg) and anti-PD-1 Ab (200 μg/mice) was administered 3 times per week from day 18 (tumor size: 7–8 mm). (c) Tumor growth curves. Control (Red), anti-PD-1 Ab monotherapy (Blue), PD173074 monotherapy (Yellow), and combination therapy with PD173074 and anti-PD-1 Ab (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (*p < .05, **p < .01, ***<0.001, one-way ANOVA). (d) The mice were sacrificed on day 42, and the percentages of CD4+ T cells and CD8+ T cells in TILs were evaluated with flow cytometry. (e) A representative image of MHC-class I or MHC-class II expression in immunohistochemistry on tumor (Day 42). MHC-class I (central) and MHC-class II (right) was enhanced by PD173074. H&E staining was shown in the left. Scale bars represent 100 µm. (f, g) MHC-class I and MHC-class II expression on MOC1 incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. MOC1 was treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Red: isotype control, Green: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (f) Representative data of flow cytometry. (g) Averages values of mean fluorescence intensity (MFI) by FGFR-TKIs. (*p < .05, **p < .01, ***<0.001, Student’s t test).
    Mouse Anti Human Fgfr1 Abs, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+fgfr1+abs/Mouse+anti-Human+IgG1+Fc+Secondary+Antibody+(2C11)/10__1080_slash_2162402x__2021__2021619-48-5-10
    Average 93 stars, based on 1 article reviews
    mouse anti human fgfr1 abs - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. FGFR1 as an immune adjuvant to combine with ICI in HNSCC mouse models. (a) FGFR1 expression in mouse HNSCC cell lines (MOC1) was examined by Western blotting. (b) Experimental schema. C57BL/6 mice were intradermally injected with MOC1 (1x106). PD173074 (20 mg/kg) and anti-PD-1 Ab (200 μg/mice) was administered 3 times per week from day 18 (tumor size: 7–8 mm). (c) Tumor growth curves. Control (Red), anti-PD-1 Ab monotherapy (Blue), PD173074 monotherapy (Yellow), and combination therapy with PD173074 and anti-PD-1 Ab (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (*p < .05, **p < .01, ***<0.001, one-way ANOVA). (d) The mice were sacrificed on day 42, and the percentages of CD4+ T cells and CD8+ T cells in TILs were evaluated with flow cytometry. (e) A representative image of MHC-class I or MHC-class II expression in immunohistochemistry on tumor (Day 42). MHC-class I (central) and MHC-class II (right) was enhanced by PD173074. H&E staining was shown in the left. Scale bars represent 100 µm. (f, g) MHC-class I and MHC-class II expression on MOC1 incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. MOC1 was treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Red: isotype control, Green: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (f) Representative data of flow cytometry. (g) Averages values of mean fluorescence intensity (MFI) by FGFR-TKIs. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Journal: OncoImmunology

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma

    doi: 10.1080/2162402x.2021.2021619

    Figure Lengend Snippet: Figure 1. FGFR1 as an immune adjuvant to combine with ICI in HNSCC mouse models. (a) FGFR1 expression in mouse HNSCC cell lines (MOC1) was examined by Western blotting. (b) Experimental schema. C57BL/6 mice were intradermally injected with MOC1 (1x106). PD173074 (20 mg/kg) and anti-PD-1 Ab (200 μg/mice) was administered 3 times per week from day 18 (tumor size: 7–8 mm). (c) Tumor growth curves. Control (Red), anti-PD-1 Ab monotherapy (Blue), PD173074 monotherapy (Yellow), and combination therapy with PD173074 and anti-PD-1 Ab (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (*p < .05, **p < .01, ***<0.001, one-way ANOVA). (d) The mice were sacrificed on day 42, and the percentages of CD4+ T cells and CD8+ T cells in TILs were evaluated with flow cytometry. (e) A representative image of MHC-class I or MHC-class II expression in immunohistochemistry on tumor (Day 42). MHC-class I (central) and MHC-class II (right) was enhanced by PD173074. H&E staining was shown in the left. Scale bars represent 100 µm. (f, g) MHC-class I and MHC-class II expression on MOC1 incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. MOC1 was treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Red: isotype control, Green: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (f) Representative data of flow cytometry. (g) Averages values of mean fluorescence intensity (MFI) by FGFR-TKIs. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Article Snippet: The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific).

    Techniques: Adjuvant, Expressing, Western Blot, Injection, Control, Flow Cytometry, Immunohistochemistry, Staining, Incubation, Fluorescence

    Figure 2. The changes of HLA and CIITA expression on HNSCC cell lines by FGFR1-TKIs. (a) FGFR1 expression in human HNSCC cell lines was examined by Western blotting. Jurkat (leukemia cells) was used as a negative control. (b, c) HLA-class I and HLA-DR and expression on HNSCC cell lines incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Green: isotype control, Red: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (b) Representative data of flow cytometry. (c) Averages values of mean fluorescence intensity (MFI). (d-g) FGFR-TKIs (3 μM) upregulated CIITA expression in HNSCC cell lines. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. (d) Representative data of Western blotting without IFN-γ. (e) Quantitative analysis of protein expression. (f) Representative data of Western blotting with IFN-γ. (g) Quantitative analysis of protein expression. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Journal: OncoImmunology

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma

    doi: 10.1080/2162402x.2021.2021619

    Figure Lengend Snippet: Figure 2. The changes of HLA and CIITA expression on HNSCC cell lines by FGFR1-TKIs. (a) FGFR1 expression in human HNSCC cell lines was examined by Western blotting. Jurkat (leukemia cells) was used as a negative control. (b, c) HLA-class I and HLA-DR and expression on HNSCC cell lines incubated with 3 μM FGFR-TKIs for 48 hr were evaluated by flow cytometry. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. Green: isotype control, Red: untreated tumor cell lines, Blue: treated with PD173074. Pink: treated with AZD4547. Orange: treated with Erdafitinib. (b) Representative data of flow cytometry. (c) Averages values of mean fluorescence intensity (MFI). (d-g) FGFR-TKIs (3 μM) upregulated CIITA expression in HNSCC cell lines. HNSCC cell lines were treated with or without 50 U/ml IFN-γ for 48 hr before the assay. (d) Representative data of Western blotting without IFN-γ. (e) Quantitative analysis of protein expression. (f) Representative data of Western blotting with IFN-γ. (g) Quantitative analysis of protein expression. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Article Snippet: The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific).

    Techniques: Expressing, Western Blot, Negative Control, Incubation, Flow Cytometry, Control, Fluorescence

    Figure 5. Direct killing of FGFR1 expressing HNSCC cells by FGFR1305-319-reactiveCD4+ T cell lines. (a) FGFR1305-319-reactive CD4+ T cell lines were co-cultured with HLA-DR matched or unmatched HNSCC cell lines expressing FGFR1 for 48 hr. K1 and K3 were restricted to HLA-DR4, and K2 was restricted to HLA-DR53. The cell lines used were HSC2 (HLA-DR13), HSC3 (HLA-DR15), HSC4 (HLA-DR1,4, and 53), Sa-3 (HLA-DR9, 10, and 53), and HPC-92Y (HLA-DR4, 9, and 53). HNSCC cell lines were treated with 500 U/ml IFN-γ for 48 hr before the assay. IFN-γ production in the supernatants was evaluated by ELISA. (b) Granzyme-B production from FGFR1305-319-reactive CD4+ T cell line (K1: HLA-DR4 restricted) was assessed in supernatants co-cultured with HLA-DR matched or unmatched HNSCC cell lines. (c) Killing activity of FGFR1305-319-reactive CD4+ T cell line (K1) was evaluated by co-culturing with CSFE-labeled HNSCC cell lines for 6 hr with various E: T (Effector: Target cells) ratio, and measuring percentages of CFSE+ 7-AAD+ dead cells with flow cytometry. (d) Representative data of flow cytometry in the killing assay (Effector to target ratio was 20:1). Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Journal: OncoImmunology

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma

    doi: 10.1080/2162402x.2021.2021619

    Figure Lengend Snippet: Figure 5. Direct killing of FGFR1 expressing HNSCC cells by FGFR1305-319-reactiveCD4+ T cell lines. (a) FGFR1305-319-reactive CD4+ T cell lines were co-cultured with HLA-DR matched or unmatched HNSCC cell lines expressing FGFR1 for 48 hr. K1 and K3 were restricted to HLA-DR4, and K2 was restricted to HLA-DR53. The cell lines used were HSC2 (HLA-DR13), HSC3 (HLA-DR15), HSC4 (HLA-DR1,4, and 53), Sa-3 (HLA-DR9, 10, and 53), and HPC-92Y (HLA-DR4, 9, and 53). HNSCC cell lines were treated with 500 U/ml IFN-γ for 48 hr before the assay. IFN-γ production in the supernatants was evaluated by ELISA. (b) Granzyme-B production from FGFR1305-319-reactive CD4+ T cell line (K1: HLA-DR4 restricted) was assessed in supernatants co-cultured with HLA-DR matched or unmatched HNSCC cell lines. (c) Killing activity of FGFR1305-319-reactive CD4+ T cell line (K1) was evaluated by co-culturing with CSFE-labeled HNSCC cell lines for 6 hr with various E: T (Effector: Target cells) ratio, and measuring percentages of CFSE+ 7-AAD+ dead cells with flow cytometry. (d) Representative data of flow cytometry in the killing assay (Effector to target ratio was 20:1). Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test).

    Article Snippet: The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific).

    Techniques: Expressing, Cell Culture, Enzyme-linked Immunosorbent Assay, Activity Assay, Labeling, Flow Cytometry

    Figure 6. The existence of FGFR1-reactive precursor T cells in HNSCC patients. (a) PBMCs from HNSCC patients were co-cultured with FGFR1305-319 peptides for 2 cycles every one week. T cell response to FGFR305-319 peptide was assessed by measuring IFN-γ production in the supernatants using ELISA. Anti-HLA-DR mAb was used to assess HLA restriction of the T cells. PADRE peptide was used as a positive control. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test). (b) The clinical characteristics and peptide-reactivity of the 6 HNSCC patients. <: less than the lower limit of detection.

    Journal: OncoImmunology

    Article Title: Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma

    doi: 10.1080/2162402x.2021.2021619

    Figure Lengend Snippet: Figure 6. The existence of FGFR1-reactive precursor T cells in HNSCC patients. (a) PBMCs from HNSCC patients were co-cultured with FGFR1305-319 peptides for 2 cycles every one week. T cell response to FGFR305-319 peptide was assessed by measuring IFN-γ production in the supernatants using ELISA. Anti-HLA-DR mAb was used to assess HLA restriction of the T cells. PADRE peptide was used as a positive control. Each data was representative in the triplicate experiments. Bars and error bars show the mean and SD, respectively. (*p < .05, **p < .01, ***<0.001, Student’s t test). (b) The clinical characteristics and peptide-reactivity of the 6 HNSCC patients. <: less than the lower limit of detection.

    Article Snippet: The membrane was incubated with mouse anti-human FGFR1 Abs (M19B2, Novus Biologicals) and mouse anti-human βactin Abs (C4, Santa Cruz Biotechnology, Santa Cruz, CA) and detected via chemiluminescence using the Amersham ECL Prime Western blotting Detection System (GE Healthcare Life Sciences) and Invitrogen iBright Imaging Systems 1500 (Invitrogen, Thermo Fisher Scientific).

    Techniques: Cell Culture, Enzyme-linked Immunosorbent Assay, Positive Control